Isotope, All-Regional Association

JSC "B/O" Isotop "is the official supplier of products of the isotope complex of ROSATOM to the international market and a key supplier of these products to the domestic market. The company was founded in 1958.

History

2022: Provision of Russian medical institutions with domestic products for radionuclide diagnostics and therapy

The Isotop All-Regional Association (part of the Rusatom Healthcare division, which accumulates Rosatom State Corporation's expertise in the field of healthcare) promptly provided Russian medical institutions with domestic products for radionuclide diagnostics and therapy. This was announced on April 5, 2022 by Zdrav.Expert at Rusatom Healthcare.

Rosatom replaced imported products for radionuclide diagnostics and therapy
Photo: pharmprom.ru

Radioisotope diagnosis enables early detection of diseases and timely initiation of treatment, which may also include the use of effective therapeutic radiopharmaceuticals when indications are available. Some medical institutions of the Russian Federation have previously used isotope products of both Russian and foreign production. Rosatom enterprises managed to organize the technological sovereignty of these products in a short time, the company said.

The "B/O" Isotope "provides the necessary amount of radionuclide products for diagnosis and therapy to the medical institutions of the country on a weekly basis. And makes a nuclear meditsinyAO most part of isotope products of "NIFHI of L.Ya. Karpov" - the center of production of radiopharmaceutical medicines and active pharmaceutical substances which is steadily closing needs of the Russian physicians and patients for the most demanded radiopharmaceuticals on the basis of iodine-131 and technetium-99m.

Technetium-99m generators are used in the diagnosis of oncological cardiological, neuroendocrine and other diseases when conducting procedures on. SPECT Iodine-131-based radiopharmaceuticals are used in the therapy of thyroid diseases.

Radiopharmaceutical (iodine-131) production Hungary and medical products (technetium-99m generators) production and were previously available on the Russian market France. In Poland connection with the current logistic situation, deliveries of short-lived products from the European states have been stopped. According to Rusatom Healthcare, they are completely replaced by domestic products. In particular, for technology generators, the share of the State Corporation "" in the Rosatom Russian market as of April 2022 is 100%.

For more than 50 years, V/O Isotope has been supplying products of L.Ya. Karpov NIFHI to clinics throughout Russia. The geography of supplies covers all regions of Russia - more than 180 radionuclide branches from Kaliningrad to Vladivostok.

"Uninterrupted and safe deliveries of short-lived radionuclide products for nuclear medicine have always been and remain one of the key priorities of ROSATOM. The expertise of enterprises of the domestic nuclear industry in the production of these products takes more than half a century. Ensuring the availability of nuclear medicine technologies in the regions of the Russian Federation, including in-demand radiopharmaceuticals, is of important social importance, as it is directly related to health care measures aimed at combating cancer and other common diseases in the country, "said Anton Shargin, Deputy General Director for Commercial Affairs" B/O "Isotope."

Radioisotope products medical of ROSATOM State Corporation purpose allow to carry out about one million diagnostic and therapeutic procedures Russia annually.

Other enterprises of ROSATOM State Corporation, including NSC NIIAR (JSC Science and Innovation), as well as the Leningrad NPP (Rosenergoatom concern), are involved in the technological chain of radiopharmaceuticals as part of import substitution. For example, targets for further production of iodine-131-based radiopharmaceuticals at the site "NIFHI named after L.Ya. Karpova" are irradiated at the Leningrad NPP.

Among the partners of JSC "B/O" Isotop "for April 2022 are more than 100 foreign companies located in 50 countries of the world, and about 600 organizations in Russia, including medical institutions, industrial enterprises and scientific organizations.

2019: Agreement with the Italian region of Puglia on understanding in the field of nuclear medicine